Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Canagliflozin Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 known ✓ | P31639 | 20/20 | 1.00 |
| ▸ | SLC5A1 | P13866 | 6/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.98 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Canagliflozin Anhydrous SCHEMBL23930431 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL681039 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL322058 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL322059 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL28454075 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL19493519 | 0.99 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL19493514 | 0.99 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL15888791 | 0.99 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL16075101 | 0.99 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL24037935 | 0.99 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 516 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250352559-A1 | Transdermal Delivery Composition for Delivery of at least one Glucose Controlling Agent, and Method of Delivering at least one Glucose Controlling Agent | SKINVISIBLE PHARMACEUTICALS INC (US) | 2025-11-20 | — | — | US | claimed |
| WO-2025137151-A2 | DENDRIMER COMPOSITIONS FOR THE TREATMENT OF ATHEROSCLEROSIS, OBESITY, AND METABOLIC SYNDROMES | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-06-26 | — | — | WO | claimed |
| WO-2025129029-A2 | COMBINATIONS OF FORALUMAB WITH GLUCAGON-LIKE PEPTIDE 1 (GLP-1) AGONISTS OR SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITORS AND METHODS OF USE THEREOF | TIZIANA LIFE SCIENCES PLC (GB) | 2025-06-19 | — | — | WO | claimed |
| US-20250064834-A1 | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF DISEASES UTILIZING TIRILAZAD SALTS | PRENDERGAST PATRICK T (IE) | 2025-02-27 | — | — | US | claimed |
| EP-3375452-B1 | USE OF LAMBDA INTERFERONS IN THE TREATMENT OF AN OBESITY-RELATED DISORDER, ATHEROSCLEROSIS OR A COAGULATION DISORDER | ANDREAKOS EVANGELOS (GR) | 2025-01-08 | — | — | EP | claimed |
| EP-3804716-B1 | PHARMACEUTICAL COMBINATION, COMPOSITION, AND COMBINATION PREPARATION COMPRISING GLUCOKINASE ACTIVATOR AND SGLT-2 INHIBITOR AND PREPARATION METHODS AND USES THEREOF | HUA MEDICINE SHANGHAI LTD (CN) | 2024-12-25 | — | — | EP | claimed |
| EP-4475853-A1 | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF DISEASES UTILIZING TIRILAZAD SALTS | Prendergast, Patrick T. (IE) | 2024-12-18 | — | — | EP | claimed |
| US-20240285653-A1 | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF DISEASES UTILIZING TIRILAZAD SALTS | PRENDERGAST PATRICK T (AU) | 2024-08-29 | — | — | US | claimed |
| US-20240261447-A1 | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS RELATED TO THE HEPATOPANCREATIC ANATOMICAL REGION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-08-08 | — | — | US | claimed |
| US-11992477-B2 | Pharmaceutical combination, composition, and combination preparation comprising glucokinase activator and SGLT-2 inhibitor and preparation methods and uses thereof | HUA MEDICINE (SHANGHAI) LTD. (CN) | 2024-05-28 | — | — | US | claimed |
| EP-4232597-A1 | METHODS OF ASSESSING RISK OF DEVELOPING A DISEASE | Genetic Technologies Limited (AU) | 2023-08-30 | — | — | EP | claimed |
| WO-2023154647-A1 | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF DISEASES UTILIZING TIRILAZAD SALTS | PRENDERGAST PATRICK T (IE) | 2023-08-17 | — | — | WO | claimed |
| WO-2023009424-A1 | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS RELATED TO THE HEPATOPANCREATIC ANATOMICAL REGION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-02-02 | — | — | WO | claimed |
| CN-114591313-A | Preparation method of canagliflozin | 南京圣鼎医药科技有限公司 | 2022-06-07 | — | — | CN | claimed |
| CN-114478501-A | Method for preparing stable canagliflozin hemihydrate crystal form | 杭州中美华东制药有限公司 | 2022-05-13 | — | — | CN | claimed |
| WO-2022082261-A1 | METHODS OF ASSESSING RISK OF DEVELOPING A DISEASE | GENETIC TECHNOLOGIES LIMITED (AU) | 2022-04-28 | — | — | WO | claimed |
| WO-2022051316-A1 | FIXED DOSE COMBINATIONS OF CHS-131 AND A SGLT-2 INHIBITOR | Coherus Biosciences, Inc. (US) | 2022-03-10 | — | — | WO | claimed |
| WO-2022051323-A1 | FIXED DOSE COMBINATIONS OF CHS-131 AND A PPAR AGONIST | Coherus Biosciences, Inc. (US) | 2022-03-10 | — | — | WO | claimed |
| WO-2022051318-A1 | FIXED DOSE COMBINATIONS OF CHS-131 AND A THYROID RECEPTOR BETA AGONIST | Coherus Biosciences, Inc. (US) | 2022-03-10 | — | — | WO | claimed |
| EP-3955913-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES | ENZYCHEM LIFESCIENCES (KR) | 2022-02-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240285653-A1 | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF DISEASES UTILIZING TIRILAZAD SALTS | TTR, MTPN, CYP24A1 | SLC5A2 1321/4885SLC5A1 627/4885ABCB11 3308/4885 |
| US-20240261447-A1 | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS RELATED TO THE HEPATOPANCREATIC ANATOMICAL REGION | PNLIP, PYGL, RXFP1 | SLC5A2 915/4885SLC5A1 821/4885ABCB11 242/4885 |
| US-20250064834-A1 | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF DISEASES UTILIZING TIRILAZAD SALTS | CYP24A1, IL23R, IL17A | SLC5A2 3500/4885SLC5A1 2444/4885ABCB11 3898/4885 |
| US-20250352559-A1 | Transdermal Delivery Composition for Delivery of at least one Glucose Controlling Agent, and Method of Delivering at least one Glucose Controlling Agent | SLC2A1, SLC2A4, SLC2A8 | SLC5A2 8/4885SLC5A1 7/4885ABCB11 324/4885 |
| US-11992477-B2 | Pharmaceutical combination, composition, and combination preparation comprising glucokinase activator and SGLT-2 inhibitor and preparation methods and uses thereof | SLC5A2, SLC5A1, GCK | SLC5A2 1/4885SLC5A1 2/4885ABCB11 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.